526 / 604
•
Is SBRT replacing systemic therapy?
•
Or should they be combined?
•
TOAD trial
(Duchesne et al, ASCO 2015): immediate versus delayed ADT
at PSA relapse aSer defini(ve therapy
–
HR=0.55 (CI: 0.30-‐1.00)
•
CHAARTED-‐
(Sweeney et al NEJM 2015): ADT+docetaxel versus ADT alone
in advanced stage hormone sensi(ve PCa
–
HR=0.61 (CI: 0.47-‐0.80)
–
m-‐OS: 58 and 44 months, respec(vely
•
STAMPEDE
(James et al Lancet 2016): SOC+docetaxel versus SOC in
advanced stage hormone sensi(ve PCa
–
HR=0·∙78 (CI: 0·∙66–0·∙93)
•
Combina(on with immune s(mula(ng agents
SBRT of prostate cancer and systemic therapies